147318-81-8|KNI-272|(R)-N-(tert-butyl)-3-((2S,3S)-2-hydroxy-3-((R)-2-(2-(isoquinolin-5-yloxy)acetamido)-3-(methylthio)propanamido)-4-phenylbutanoyl)thiazolidine-4-carboxamide|-范德生物科技公司

KNI-272

NMR下载 COA and HPLC MSDS下载
names：
(R)-N-(tert-butyl)-3-((2S,3S)-2-hydroxy-3-((R)-2-(2-(isoquinolin-5-yloxy)acetamido)-3-(methylthio)propanamido)-4-phenylbutanoyl)thiazolidine-4-carboxamide
CAS号：
147318-81-8
MDL Number：
MF(分子式)： C33H41N5O6S2 MW(分子量)： 667.84
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	KNI-272
英文别名	Kynostatin-272; Kynostatin 272; Kynostatin272; KNI-272; NSC-651714; KNI272; NSC651714; DRG-0219; DRG 0219; DRG0219.
CAS号	147318-81-8
SMILES	O=C([C@H]1N(C([C@@H](O)[C@@H](NC([C@@H](NC(COC2=CC=CC3=C2C=CN=C3)=O)CSC)=O)CC4=CC=CC=C4)=O)CSC1)NC(C)(C)C
Inchi	InChI=1S/C33H41N5O6S2/c1-33(2,3)37-31(42)26-19-46-20-38(26)32(43)29(40)24(15-21-9-6-5-7-10-21)36-30(41)25(18-45-4)35-28(39)17-44-27-12-8-11-22-16-34-14-13-23(22)27/h5-14,16,24-26,29,40H,15,17-20H2,1-4H3,(H,35,39)(H,36,41)(H,37,42)/t24-,25-,26-,29-/m0/s1
InchiKey	NJBBLOIWMSYVCQ-VZTVMPNDSA-N
分子式 Formula	C33H41N5O6S2
分子量 Molecular Weight	667.84
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	KNI-272(CAS:147318-81-8):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Kynostatin-272, also known as KNI-272; NSC-651714; DRG-0219, is a HIV protease inhibitor potentially for the treatment of HIV infection. KNI-272 blocked the maturation of viral particles. Consequently, KNI-272 has at least two inhibition targets in the stages of the HIV-1 life cycle.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Adachi M, Ohhara T, Kurihara K, Tamada T, Honjo E, Okazaki N, Arai S, Shoyama Y, Kimura K, Matsumura H, Sugiyama S, Adachi H, Takano K, Mori Y, Hidaka K, Kimura T, Hayashi Y, Kiso Y, Kuroki R. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4641-6. doi: 10.1073/pnas.0809400106. PubMed PMID: 19273847; PubMed Central PMCID: PMC2660780.

[2]Matsumura H, Adachi M, Sugiyama S, Okada S, Yamakami M, Tamada T, Hidaka K, Hayashi Y, Kimura T, Kiso Y, Kitatani T, Maki S, Yoshikawa HY, Adachi H, Takano K, Murakami S, Inoue T, Kuroki R, Mori Y. Crystallization and preliminary neutron diffraction studies of HIV-1 protease cocrystallized with inhibitor KNI-272. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 Nov 1;64(Pt 11):1003-6. doi: 10.1107/S1744309108029679. PubMed PMID: 18997326; PubMed Central PMCID: PMC2581681.

[3] Doi M, Kimura T, Ishida T, Kiso Y. Rigid backbone moiety of KNI-272, a highly selective HIV protease inhibitor: methanol, acetone and dimethylsulfoxide solvated forms of 3-[3-benzyl-2-hydroxy-9-(isoquinolin-5-yloxy)-6-methylsulfanylmethyl-5,8-dioxo-4, 7-diazanonanoyl]-N-tert-butyl-1,3-thiazolidine-4-carboxamide. Acta Crystallogr B. 2004 Aug;60(Pt 4):433-7. PubMed PMID: 15258401.

[4] Doi M, Ishida T, Katsuya Y, Sasaki M, Taniguchi T, Hasegawa H, Mimoto T, Kiso Y. KNI-272, a highly selective and potent peptidic HIV protease inhibitor. Acta Crystallogr C. 2001 Nov;57(Pt 11):1333-5. PubMed PMID: 11706266.

[5] Churchill DR, Slade PM, Youle M, Gazzard BG, Weber JN. A phase I/II study of the safety and activity of a microsphere formulation of KNI-272 in patients with HIV-1 infection. J Antimicrob Chemother. 2001 Mar;47(3):353-5. PubMed PMID: 11222570.

6: Goto T, Nakano T, Kohno T, Morimatsu S, Morita C, Hong W, Kiso Y, Nakai M, Sano K. Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells. J Med Virol. 2001 Mar;63(3):203-9. PubMed PMID: 11170058.7: Velazquez-Campoy A, Luque I, Todd MJ, Milutinovich M, Kiso Y, Freire E. Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci. 2000 Sep;9(9):1801-9. PubMed PMID: 11045625; PubMed Central PMCID: PMC2144700.8: Kiriyama A, Nishiura T, Yamaji H, Takada K. Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor. Biopharm Drug Dispos. 1999 May;20(4):199-205. PubMed PMID: 10440795.9: Humphrey RW, Wyvill KM, Nguyen BY, Shay LE, Kohler DR, Steinberg SM, Ueno T, Fukasawa T, Shintani M, Hayashi H, Mitsuya H, Yarchoan R. A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection. Antiviral Res. 1999 Feb;41(1):21-33. PubMed PMID: 10321576.10: Kiriyama A, Nishiura T, Yamaji H, Takada K. Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Antimicrob Agents Chemother. 1999 Mar;43(3):549-56. PubMed PMID: 10049266; PubMed Central PMCID: PMC89159.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开